OSTEOPOROSIS ENROLLMENT FORM

	BAPTIST	DATE: DATE NEEDED:		SHIP TO: □ PATIENT □ OFFICE					
► NAME: E-MAIL_					D	OB:		 E □ FEMALE	
PATIENT INFO OH OH	ADDRESS:			CITY		STAT	E ZIP		
PA HO	ME TELEPHONE:			ILE PHONE:					
INSUF	RANCE INFO:	PLEASE		URANCE CARD (FRONT & BACK)					
	Diagnosis • Date of Diagnosis:			Patient Evaluation - General					
ORMATION	□ M88.9 Paget's Disease			■ Treatment History: □ new to this medicine □ continued treatment					
	☐ M80.80 Unspecified Osteoporosis			**If continuing on FORTEO®, what is start date of treatment?					
	☐ M81.0 Postmenopausal/Senile Osteoporosis			(Forteo [®] can be taken for a maximum of 24 months)					
	☐ M81.8 Drug-induced Osteoporosis			◆ Allergies? □ None □ Latex □ Other:					
0	☐ M80.88 Pathological Fracture of Vertebrae			Patient weight:lb/kg					
INF	☐ M80.85 Pathological Fracture of Neck of Femur			Concomitant Medications:					
	\square M89.9 Unspecified disorder of bones \square M94.9 of cartilage			Patient Evaluation - Osteoporosis					
NICAI	Primary Care Physician:			• Lowest Dexa T-Score: Date of Dexa:					
Ž	Primary Physician Phone #:						f fracture:		
	Prior Failed Med	Prior Failed Medication(s)		Length of Treatment Reason		Reason for Dis	or Discontinuing		
				to					
				to					
NFORMATION	Drug	Dosage form/strength		Directions			Quantity	Refills	
	□ Boniva®	□ Prefilled Syring	e (3mg/3ml)	$_{\square}$ Inject 3mg IV over 15-30 seconds every 3 months		1 syringe (3mg/3ml)			
	□ Forteo®	orteo® Pen (600ug/2.4ml) Delivery Device			☐ Inject 20mcg (0.08ml) SQ daily				
	Complimentary 4mm 5mm 8mm Needles 32G 31G 31G			☐ Use with Forteo® Delivery Device as directed			30		
	□ Please enroll patient in FORTEO® Connect patient support program								
	□ Prolia®	□ Prefilled Syringe (60mg/ml)		☐ Inject 60mg SQ once every 6 months		1 pen (60mg/ml)			
Z	Zoledronic			☐ Infuse 5mg IV, over no less than 15 minutes, every year		1 vial			
NO	□ Acid			☐ Infuse 5mg IV, over no less than 15 minutes, every 2 years			(5mg/100ml)		
CRIPTIC	OTHER MEDICATIONS								
	Drug	Dosage form/strength		Directions		Quantity	Refills		
			<u> </u>						
RES							 		
虿									
	Comments:								
	Injection Training								
	□ Patient has received pen and injection training □ Physician's office to provide injection training □ ReCept to coordinate injection training								
	MANUF SUPPORT: Please enroll patient in the product manufacturer-sponsored support program?								
		•	•	Contact Parson					
T ON T	elephone: Fav.			Contact Person: Email:					
NAT (office Address:			City:State: Zip:			D:		
PRESCRIBER NFORMATION	NPI # :	DEA # :		Email: State: Zip: City: State: Zip: UPIN # : Medicaid Provider # :					
	* RESCRIBER'S SIGNATURE (DATE) *IF BRAND DRUGS ARE PREFERRED, HANDWRITE "BRAND MEDICALLY NECESSARY" ABOVE								
	authorize the Pharmacy n	Ithorize the Pharmacy noted above and its representatives to act as an agent to initiate and execute the insurance prior authorization process. ©Recept, LP All rights Reserved Company Compan							

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.